LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: An update on the microbiome in vasculitis.

    Tariq, Shahna / Clifford, Alison H

    Current opinion in rheumatology

    2020  Volume 33, Issue 1, Page(s) 15–23

    Abstract: Purpose of review: To summarize recent evidence regarding the presence and potential role of the microbiome in systemic vasculitides.: Recent findings: Microbiomic descriptions are now available in patients with small, medium and large vessel ... ...

    Abstract Purpose of review: To summarize recent evidence regarding the presence and potential role of the microbiome in systemic vasculitides.
    Recent findings: Microbiomic descriptions are now available in patients with small, medium and large vessel vasculitis. The majority of studies have evaluated gastrointestinal inhabitants, with a smaller number of studies describing the nasal, pulmonary or vascular microbiomes. Most published studies are observational and cross-sectional. Dysbiosis is seen frequently in vasculitis patients with reduced microbial diversity observed in nasal, fecal and vascular samples compared with disease and/or healthy controls. Predominant bacteria vary, but overall, patients with vasculitis tend to have more pathogenic and less commensal bacteria in active disease. In the few longitudinal studies available, improvement or resolution of dysbiosis has been observed following vasculitis treatment and improved disease activity.
    Summary: Dysbiosis and reduced microbial diversity has been identified in patients with small, medium and large vessel vasculitis. Although limited data suggests microbiomes may 'normalize' following immunosuppression, cause or effect cannot be determined. It is hypothesized that microbial disruption in a genetically susceptible individual may trigger excessive host immune activation and vasculitis; however, larger studies with longitudinal and translational design are needed to further our current understanding.
    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/microbiology ; Bacteria/isolation & purification ; Cross-Sectional Studies ; Dysbiosis/microbiology ; Feces/microbiology ; Giant Cell Arteritis/microbiology ; Humans ; Longitudinal Studies ; Microbiota ; Nose/microbiology ; Symbiosis ; Systemic Vasculitis/microbiology ; Vasculitis/microbiology
    Language English
    Publishing date 2020-11-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000758
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3028: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Diagnosis of pulmonary arterial hypertension preceding the confirmation of systemic sclerosis in a patient with Raynaud's phenomenon.

    Tariq, Shahna / Tervaert, Jan Willem Cohen / Osman, Mohammed

    Microvascular research

    2021  Volume 139, Page(s) 104267

    MeSH term(s) Anticoagulants/therapeutic use ; Antihypertensive Agents/therapeutic use ; Capillaries/diagnostic imaging ; Cardiac Catheterization ; Female ; Fingers/blood supply ; Humans ; Microscopic Angioscopy ; Middle Aged ; Predictive Value of Tests ; Pulmonary Arterial Hypertension/diagnosis ; Pulmonary Arterial Hypertension/drug therapy ; Pulmonary Arterial Hypertension/etiology ; Raynaud Disease/diagnostic imaging ; Raynaud Disease/drug therapy ; Raynaud Disease/etiology ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/diagnostic imaging ; Scleroderma, Systemic/drug therapy ; Treatment Outcome
    Chemical Substances Anticoagulants ; Antihypertensive Agents
    Language English
    Publishing date 2021-10-16
    Publishing country United States
    Document type Case Reports ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80307-8
    ISSN 1095-9319 ; 0026-2862
    ISSN (online) 1095-9319
    ISSN 0026-2862
    DOI 10.1016/j.mvr.2021.104267
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 746: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: COVID-19, rheumatic diseases and immune dysregulation-a perspective.

    Tariq, Shahna / Van Eeden, Charmaine / Tervaert, Jan Willem Cohen / Osman, Mohammed S

    Clinical rheumatology

    2021  Volume 40, Issue 2, Page(s) 433–442

    Abstract: The COVID-19 pandemic has resulted in widespread hospitalisations and deaths around the world. As patients with rheumatic diseases generally have increased risk of infections and complications, understandably, there is significant concern of the impact ... ...

    Abstract The COVID-19 pandemic has resulted in widespread hospitalisations and deaths around the world. As patients with rheumatic diseases generally have increased risk of infections and complications, understandably, there is significant concern of the impact of SARS-CoV-2 on these patients. However, there is a paucity of data in rheumatic patients. We review mechanisms through which SARS-CoV-2 results in infection, including ACE2 receptor, and complications (including immune dysregulation, thrombosis and complement activation). We assess these pathways in patients with rheumatic disease and those on immune modulating therapy. Although data thus far does not appear to show worse outcomes in rheumatic patients as a whole, given alterations in the underlying immune pathways in certain diseases (such as systemic lupus erythematosus), we posit that the risk is not equal in all rheumatic patients. We also discuss the benefit of underlying disease control with respect to COVID-19 risk reduction and potential increased risk of disease flares following viral infection from an immune standpoint.
    MeSH term(s) Autoimmune Diseases/epidemiology ; Autoimmune Diseases/immunology ; Autoimmunity ; COVID-19/epidemiology ; Humans ; Pandemics ; Rheumatic Diseases/epidemiology ; Rheumatic Diseases/immunology ; SARS-CoV-2
    Language English
    Publishing date 2021-01-07
    Publishing country Germany
    Document type Editorial
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-020-05529-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1740: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top